A case report of long term bevacizumab treatment in multiresistant ovarian cancer
<p>Treatment of multiresistant ovarian cancer is palliative and patients have needs for less toxic treatment. Anti-angiogenic treatments have a less toxic profile, and bevacizumab has shown improvement of progression free survival (PFS) in front-line trials. Bevacizumab is generally introduced...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IJCTO
2016-06-01
|
| Series: | International Journal of Cancer Therapy and Oncology |
| Subjects: | |
| Online Access: | http://ijcto.org/index.php/IJCTO/article/view/513 |